Tempus AI Pre-lim Results
For those following AI Healthcare stocks - TEM pre-lim Q4 & full year 2025 results out 5pm EST today. Usually positive news when released early and ahead of tomorrows JP Morgan Healthcare Conference starting in SF
Tempus AI, a leader in AI-driven precision medicine, announced preliminary results for Q4 and full year 2025, showing nearly doubled revenue of approximately $1.27 billion, with diagnostics revenue at $955 million and data and applications revenue reaching $100 million in Q4. Diagnostics revenue grew by 111% year-over-year, driven by oncology and hereditary volume growth, while data and applications revenue grew by 31%, with Insights growing by 38%.